Best MCIC Shareholder newsletter EVER:
Dear MultiCorp International, Inc. Shareholders,
These are exciting times as we move forward with the migraine medication as the sole focus for our company. The feedback we have
received from the FDA has given us a clear roadmap for taking this product through the next step. Having worked with Dr. Salehani in
collaboration with MCIC over the past 2 years in support of the development of the migraine medicine, I know the value of Dr Salehani’s
prior studies as well as the information he was able to provide the FDA on patients he has treated with this medication, which was useful
in the generation of the FDA’s report.
We believe that the valuation on the patent warranted the company in suspending all other operations in order to focus 100% of our
energy on being a pharmaceutical and medical company. As part of that transition, I have agreed to take the position as interim CEO in
order to advance MultiCorp in these areas. I have offered my 35 years of experience in the health care industry because I feel the
migraine medicine should get FDA approval and become a significant solution for the treatment of migraine headaches. In addition, we
are exploring other opportunities for the company which could add to the growth and value of the company going forward. By capitalizing
on my experience and using my knowledge of the healthcare industry the company can and will identify other avenues for revenue in the
medical industry.
In the last couple of weeks, we have been in discussions with companies with the potential to facilitate the 4-arm study in the Emergency
Room setting which the FDA has stated should be the site in which our trials take place. As I’m sure you realize, the FDA has high
expectations regarding accuracy and transparency in the conducting of and reporting of these trials, which will be time consuming and
costly. Accordingly, we will be partnering with firms that have the experience and depth necessary in order to satisfy the standards
established by the FDA.
The response from the FDA outlines that upon successful completion of the 4-arm, proof of concept study, the medicine will be ready for
phase 3 of the clinical trials. This allows us to skip Phases 1 and 2 clinical trials in part because of previous clinical research that has been
done. Having our medication placed in Phase 3 clinical trial status automatically places a higher valuation on the patent and significantly
increases the chances of it getting final FDA approval in order to be fully commercialized. Our investment of time, money and effort in the
pre-IND has already created value for the company and our shareholders.
When the 4-arm study begins, we plan on creating an advisory panel of qualified physicians in various practice areas which will assist the
company in interpreting the study findings and assist the company in its path forward. In addition, this advisory panel can open other
opportunities in the medical field that the company has not been exposed to previously.
The company’s ultimate goal is to bring this product to market. However, should the opportunity arise wherein we can capitalize on a
potential sale to a large pharma company, the Board of Directors will fully evaluate this opportunity and do what’s best for MCIC now, and
in the future.
We plan to keep our shareholders updated through proper legal channels. I look forward to growing this company into a leader in the
medical sector.
Sincerely,
David Gustafson
